ELIQUIS resources to support your patients
Co-Pay and Free Trial Offers for Your Patients Prescribed ELIQUIS
Help patients
get started on
ELIQUIS
Free 30-Day Trial & $10 Co-Pay card* for Eligible Patients^
Free 30-day trial offer for first-time patients and
co-pay assistance for eligible patients prescribed ELIQUIS.*
- This co-pay card is accepted only at participating pharmacies
- This co-pay card is not health insurance
*For commercially insured patients. Annual maximum benefit of $6,400. ^Eligibility and terms and conditions apply. Please see drop-downs below for details.
$10 CO-PAY CARD ELIGIBILITY REQUIREMENTS:
You may be eligible for the Co-pay Card for ELIQUIS® (apixaban) if:
- You are insured by commercial insurance and your prescription insurance coverage does not cover the full cost of your prescription, that is, you have a co-pay obligation for ELIQUIS;
- You do not have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), or Department of Defense (DOD) programs; patients who move from commercial plans to state or federal healthcare programs will no longer be eligible;
- You are 18 years of age or older; and
- You are a resident of the United States, Puerto Rico, or other select U.S. Territory.
$10 CO-PAY CARD TERMS OF USE:
- Eligible patients who present an activated Co-pay Card together with a valid prescription for ELIQUIS at participating pharmacies may pay as little as $10 per 30-day supply (up to 74 tablets for the first fill and up to 60 tablets for all subsequent fills) for up to 24 months, subject to a maximum annual benefit of $6400. Other restrictions may apply. Patient is responsible for applicable taxes, if any.
- Offer not applicable to co-pays of $10 or less.
- Patients, pharmacists, and prescribers cannot seek reimbursement, from health insurance or any third party, for any part of the benefit received by the patient through this offer.
- Your acceptance of this offer confirms that this offer is consistent with your insurance and that you will report the value received as may be required by your insurance provider.
- Card must be activated before use. Activation and first use of the Co-pay Card must take place by December 31, 2024. Card expires 24 months from activation. Upon expiration, eligible patients may re-enroll in the Co-pay Card Program.
- All Program payments are for the benefit of the patient only.
- Only valid in the United States, Puerto Rico, or other select U.S. Territories; this offer is void where restricted or prohibited by law.
- This offer is non-transferable, no substitutions are permissible, and offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription.
- The Co-pay Card may not be sold, purchased, traded, or counterfeited. Reproductions of this Co-pay Card are void.
- Bristol Myers Squibb and Pfizer reserve the right to rescind, revoke, or amend this offer at any time without notice.
- This offer is not conditioned on any past, present, or future purchase, including refills.
- No membership fees.
- The Co-pay Card for ELIQUIS is not health insurance.
The Co-pay Card will be accepted only at participating pharmacies. For those customers using mail order or any non-participating retail pharmacy, please call 866-279-4730 to request a patient rebate form, or go to www.patientrebateonline.com to download a form. Questions can also be submitted via mail to: P.O. Box 2914, Phoenix, AZ, 85062-2914.
BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
To the pharmacist: For processing assistance, please call McKesson Pharmacy Support at 866-279-4730.
30-DAY FREE TRIAL OFFER ELIGIBILITY REQUIREMENTS:
You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:
- You have not previously filled a prescription for ELIQUIS;
- You have a valid 30-day prescription for ELIQUIS;
- You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;
- You are 18 years of age, or older; and
- You are a resident of the United States, Puerto Rico, or other select U.S. Territory.
30-DAY FREE TRIAL OFFER TERMS OF USE:
- Eligible patients who present a Free 30-Day Trial card together with a valid 30-day prescription for ELIQUIS at participating pharmacies can receive a free 30-day supply (up to 74 tablets) of ELIQUIS. Patient is responsible for applicable taxes, if any. This offer may not be redeemed on prescriptions written for longer than 30 days.
- This offer is limited to one use per patient per lifetime and is non-transferable. By redeeming this offer, you certify that you have not previously filled a prescription for ELIQUIS.
- The Free 30-Day Trial for the specified prescription cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions are permitted.
- Patients, pharmacists, and prescribers cannot seek reimbursement for the Free 30-Day Trial of ELIQUIS from health insurance or any third party, including state or federally funded programs.
- Patients may not count the Free 30-Day Trial of ELIQUIS as an expense incurred for purposes of determining out-of-pocket costs for any plan, including true out-of-pocket costs, (TrOOP), for purposes of calculating the out-of-pocket threshold for Medicare Part D plans.
- Activation and use of the Free 30-Day Trial card must take place by December 31, 2024. This card expires on December 31, 2024.
- Only valid in the United States, Puerto Rico, or other select U.S. Territories; this offer is void where restricted or prohibited by law.
- Bristol Myers Squibb and Pfizer reserve the right to rescind, revoke, or amend this offer at any time without notice.
- This Free 30-Day Trial card may not be sold, purchased, traded, or counterfeited. Reproductions of this card are void.
- This offer is not conditioned on any past, present, or future purchase, including refills.
- The ELIQUIS Free 30-Day Trial offer is not health insurance.
BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
To the pharmacist: For processing assistance, please call McKesson Pharmacy Support at 866-279-4730.
A guide to help your patients with NVAF learn about reducing risk of stroke and systemic embolism due to Nonvalvular AFib with ELIQUIS
A guide to help your patients with VTE learn about deep vein thrombosis/pulmonary embolism treatment with ELIQUIS
ELIQUIS patient website for:
- ELIQUIS Free 30-Day Trial activation
- ELIQUIS Co-pay Card requests
- Rx coverage and reimbursement information
- ELIQUIS 360 newsletters and emails
- Patient education videos
- Patient education/resource downloads
- ELIQUIS Starter Pack
Request Samples
Samples of ELIQUIS
2.5 mg and 5 mg tablets
are available for eligible
prescribers. Call 1-855-ELIQUIS (354-7847) or click below to see if you are eligible to have samples delivered to your office.
Benefits Investigation
Get support for access to ELIQUIS.
Live Support
Specialists
Our live specialists are just a
phone call away and ready to
help you and your patients at
1-855-ELIQUIS (354-7847)
Monday–Friday, 8 AM–8 PM ET.
Benefits Reviews,
Summary of Benefits
and Follow-up Support
We can confirm plan coverage, help
estimate patient out-of-pocket
expenses, and assist with Medicare
Part D questions, plus may be able to help with prior authorizations, formulary and tiering exceptions.
Online Support
Portal
Register today and you’ll be able to:
- Access coverage resources
around-the-clock - Download forms and templates
- Track the status of open cases
- Contact your ELIQUIS representative for details
Dosing Guide
This downloadable dosing guide contains important ELIQUIS
dosing information for all of the approved indications.
Hospital Discharge Resources
Get resources and data related to discharge on ELIQUIS.
Help your patients with NVAF get started on ELIQUIS to help reduce the risk of stroke.
Help your patients with VTE get started on ELIQUIS for the treatment of DVT/PE.
Select ELIQUIS Clinical Trials
Links to select publications for ELIQUIS phase III clinical trials are provided below.
Systemic Embolism in NVAF:
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS® (apixaban), increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
- use of indwelling epidural catheters
- concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
- optimal timing between the administration of ELIQUIS and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.
- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)
- Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
- Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
- Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
- Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
- The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). An agent to reverse the anti-factor Xa activity of apixaban is available. Please visit www.andexxa.com for more information on availability of a reversal agent.
- Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.
- Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.
- Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy: Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.
- Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome (APS): Direct-acting oral anticoagulants (DOACs), including ELIQUIS, are not recommended for use in patients with triple-positive APS. For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti–beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.
- The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.
- ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.
- Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.
- Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban.
- Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.
- The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery, and in the fetus and neonate.
- Labor or delivery: ELIQUIS use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches.
- Breastfeeding is not recommended during treatment with ELIQUIS.
FEMALES AND MALES OF REPRODUCTIVE POTENTIAL
- Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. The risk of clinically significant uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including ELIQUIS should be assessed in these patients and those with abnormal uterine bleeding.
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.
Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and MEDICATION GUIDE.
ELIQUIS is available in 2.5 mg and 5 mg tablets.